Arbutus Biopharma (ABUS) Return on Capital Employed (2014 - 2026)

Arbutus Biopharma has disclosed Return on Capital Employed across 13 years of filings, most recently posting 86.54% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 86.54%, up 16531.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 86.54% (up 16531.0% YoY), and the FY2025 annual result was 35.61%, up 2672.0% from the prior year.
• Return on Capital Employed came in at 86.54% for Q1 2026 at Arbutus Biopharma, up from 42.33% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 86.54% in Q1 2026 to a low of 78.77% in Q1 2025.
• The 5-year median for Return on Capital Employed is 49.11% (2025), against an average of 43.66%.
• Across the five-year window, Return on Capital Employed sank 2128 bps in 2023 and jumped 16531 bps in 2026, its largest moves.
• Arbutus Biopharma's Return on Capital Employed stood at 39.25% in 2022, then sank by 54 bps to 60.53% in 2023, then retreated by 5 bps to 63.36% in 2024, then jumped by 33 bps to 42.33% in 2025, then jumped by 304 bps to 86.54% in 2026.
• The last three Return on Capital Employed figures came in at 86.54% (Q1 2026), 42.33% (Q4 2025), and 49.11% (Q3 2025), per Business Quant data.